MEVITEM: A European, randomized, open-label Phase I/II of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent/ refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway (original) (raw)

paper cover icon

MEVITEM: A European, randomized, open-label Phase I/II of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent/ refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway

Journal of Clinical Oncology, 2016

Abstract

TPS2083Background: Therapeutic options are limited for refractory/relapsed adult medulloblastoma with activation of sonic hedgehog pathway (SHH-MB). Inhibition of this pathway may offer an attracti...

Andreas Hottinger hasn't uploaded this paper.

Let Andreas know you want this paper to be uploaded.

Ask for this paper to be uploaded.